(CURI) Curiositystream - Ratings and Ratios
Documentaries, Streaming, Subscription, Licensing
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 9.92% |
| Yield on Cost 5y | 3.15% |
| Yield CAGR 5y | 0.00% |
| Payout Consistency | 100.0% |
| Payout Ratio | - |
| Risk via 5d forecast | |
|---|---|
| Volatility | 75.6% |
| Value at Risk 5%th | 104% |
| Relative Tail Risk | -16.03% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.51 |
| Alpha | 153.91 |
| CAGR/Max DD | 0.77 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.579 |
| Beta | 1.244 |
| Beta Downside | 1.096 |
| Drawdowns 3y | |
|---|---|
| Max DD | 76.06% |
| Mean DD | 35.34% |
| Median DD | 36.15% |
Description: CURI Curiositystream October 26, 2025
CuriosityStream Inc. (NASDAQ:CURI) is a U.S.-based media and entertainment firm that produces factual, documentary-style video and audio content across science, history, society, nature, lifestyle and technology. The library is delivered directly to consumers via its subscription-video-on-demand (SVoD) platform on internet-connected devices, and indirectly through distribution partners that bundle CuriosityStream titles into larger streaming or linear packages, as well as through bulk-sale licensing, educational talks and courses.
Key operating metrics as of the latest filing show roughly 5 million global subscribers with an average revenue per user (ARPU) of $4.90 per month and a churn rate near 8 % annually-both in line with niche streaming peers. The company’s growth is tied to macro trends such as continued cord-cutting, rising demand for ad-free, niche-content subscriptions, and the expanding global broadband penetration that fuels device-agnostic streaming. Margin improvement has been driven by a low-cost, in-house production model and scalable licensing agreements, allowing EBITDA margins to edge above 15 % in 2023.
For a deeper quantitative assessment, you might explore ValueRay’s analyst tools to compare CuriosityStream’s valuation multiples against sector peers and test scenario sensitivities.
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income (-5.45m TTM) > 0 and > 6% of Revenue (6% = 4.00m TTM) |
| FCFTA 0.16 (>2.0%) and ΔFCFTA 13.19pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 21.84% (prev 35.80%; Δ -13.95pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.16 (>3.0%) and CFO 12.1m > Net Income -5.45m (YES >=105%, WARN >=100%) |
| Net Debt (-10.1m) to EBITDA (8.66m) ratio: -1.17 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.62 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (57.4m) change vs 12m ago 7.07% (target <= -2.0% for YES) |
| Gross Margin 54.50% (prev 48.40%; Δ 6.10pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 82.08% (prev 59.13%; Δ 22.95pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -15.48 (EBITDA TTM 8.66m / Interest Expense TTM 439.0k) >= 6 (WARN >= 3) |
Altman Z'' -26.04
| (A) 0.19 = (Total Current Assets 38.0m - Total Current Liabilities 23.5m) / Total Assets 74.7m |
| (B) -4.38 = Retained Earnings (Balance) -327.1m / Total Assets 74.7m |
| warn (B) unusual magnitude: -4.38 — check mapping/units |
| (C) -0.08 = EBIT TTM -6.79m / Avg Total Assets 81.1m |
| (D) -11.89 = Book Value of Equity -327.1m / Total Liabilities 27.5m |
| Total Rating: -26.04 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 49.66
| 1. Piotroski 6.50pt |
| 2. FCF Yield 5.57% |
| 3. FCF Margin 18.09% |
| 4. Debt/Equity 0.08 |
| 5. Debt/Ebitda -1.17 |
| 6. ROIC - WACC (= -22.69)% |
| 7. RoE -10.24% |
| 8. Rev. Trend -42.05% |
| 9. EPS Trend 64.47% |
What is the price of CURI shares?
Over the past week, the price has changed by -8.37%, over one month by -17.11%, over three months by -24.50% and over the past year by +176.00%.
Is CURI a buy, sell or hold?
- Strong Buy: 0
- Buy: 2
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the CURI price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 6.3 | 65.3% |
| Analysts Target Price | 6.3 | 65.3% |
| ValueRay Target Price | 3.9 | 0.5% |
CURI Fundamental Data Overview December 19, 2025
P/E Forward = 103.0928
P/S = 3.6067
P/B = 5.0709
Beta = 1.862
Revenue TTM = 66.6m USD
EBIT TTM = -6.79m USD
EBITDA TTM = 8.66m USD
Long Term Debt = 3.99m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 420.0k USD (from shortTermDebt, last quarter)
Debt = 3.99m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -10.1m USD (from netDebt column, last quarter)
Enterprise Value = 216.4m USD (240.2m + Debt 3.99m - CCE 27.8m)
Interest Coverage Ratio = -15.48 (Ebit TTM -6.79m / Interest Expense TTM 439.0k)
FCF Yield = 5.57% (FCF TTM 12.0m / Enterprise Value 216.4m)
FCF Margin = 18.09% (FCF TTM 12.0m / Revenue TTM 66.6m)
Net Margin = -8.19% (Net Income TTM -5.45m / Revenue TTM 66.6m)
Gross Margin = 54.50% ((Revenue TTM 66.6m - Cost of Revenue TTM 30.3m) / Revenue TTM)
Gross Margin QoQ = 58.67% (prev 53.38%)
Tobins Q-Ratio = 2.90 (Enterprise Value 216.4m / Total Assets 74.7m)
Interest Expense / Debt = 11.00% (Interest Expense 439.0k / Debt 3.99m)
Taxrate = 5.24% (-207.0k / -3.95m)
NOPAT = -6.44m (EBIT -6.79m * (1 - 5.24%)) [loss with tax shield]
Current Ratio = 1.62 (Total Current Assets 38.0m / Total Current Liabilities 23.5m)
Debt / Equity = 0.08 (Debt 3.99m / totalStockholderEquity, last quarter 47.2m)
Debt / EBITDA = -1.17 (Net Debt -10.1m / EBITDA 8.66m)
Debt / FCF = -0.84 (Net Debt -10.1m / FCF TTM 12.0m)
Total Stockholder Equity = 53.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -7.30% (Net Income -5.45m / Total Assets 74.7m)
RoE = -10.24% (Net Income TTM -5.45m / Total Stockholder Equity 53.2m)
RoCE = -11.87% (EBIT -6.79m / Capital Employed (Equity 53.2m + L.T.Debt 3.99m))
RoIC = -12.09% (negative operating profit) (NOPAT -6.44m / Invested Capital 53.2m)
WACC = 10.60% (E(240.2m)/V(244.2m) * Re(10.60%) + D(3.99m)/V(244.2m) * Rd(11.00%) * (1-Tc(0.05)))
Discount Rate = 10.60% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 4.00%
[DCF Debug] Terminal Value 59.87% ; FCFE base≈8.26m ; Y1≈5.42m ; Y5≈2.48m
Fair Price DCF = 0.58 (DCF Value 33.9m / Shares Outstanding 58.3m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 64.47 | EPS CAGR: 12.65% | SUE: -0.34 | # QB: 0
Revenue Correlation: -42.05 | Revenue CAGR: -10.02% | SUE: 1.71 | # QB: 2
EPS next Quarter (2026-03-31): EPS=-0.06 | Chg30d=-0.070 | Revisions Net=+1 | Analysts=1
EPS next Year (2026-12-31): EPS=0.04 | Chg30d=N/A | Revisions Net=-1 | Growth EPS=+144.4% | Growth Revenue=+9.4%
Additional Sources for CURI Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle